BioSpace News Archive

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported today that rilvegostomig, AstraZeneca’s bi-specific antibody derived from Compugen’s COM902, is expected to progress into Phase 3 this year.

Syndax Pharmaceuticals, Inc. announced that members of its management team will participate in the upcoming investor conferences.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2022 and provided full year guidance for 2023.

LENSAR, Inc. announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of its ALLY® Adaptive Cataract Treatment System.

JSR Life Sciences, LLC announced that Similis Bio, its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop three biosimilar programs that address a wide range of hard-to-treat diseases.

Rectify Pharmaceuticals, Inc., (“Rectify”) today announced the appointments of Tuyen Ong, M.D., M.B.A., to the Board and Directors, and Jason Campagna, M.D., Ph.D., to the Scientific Advisory Board.

Research published in Nature Chemical Biology demonstrates a new tool for scientists studying conditions such as autism and Alzheimer’s disease.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009, a novel BTC™ targeting Nectin-4.

908 Devices Inc., a pioneer of handheld and desktop devices for chemical and biochemical analysis, announced it will report financial results for the fourth quarter and full year 2022 before market open on Tuesday, March 7, 2023.